

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 January 2025 (02.01.2025)



(10) International Publication Number
WO 2025/006878 A1

(51) International Patent Classification:

C07D 451/14 (2006.01) A61P 25/28 (2006.01)
A61K 31/439 (2006.01) A61P 35/00 (2006.01)
A61P 25/00 (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/036007

(22) International Filing Date:

28 June 2024 (28.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/511,248 30 June 2023 (30.06.2023) US

(71) Applicant: SKYHAWK THERAPEUTICS, INC.
[US/US]; 180 3rd Avenue, Fifth Floor, Waltham, Massachusetts 02451 (US).

(72) Inventors: LUZZIO, Michael; c/o Skyhawk Therapeutics, Inc., 180 3rd Avenue, Fifth Floor, Waltham, Massachusetts 02451 (US). LUCAS, Brian; c/o Skyhawk Therapeutics, Inc., 180 3rd Avenue, Fifth Floor, Waltham, Massachusetts 02451 (US).

(74) Agent: YOON, Koyi; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: 6-(6-(((1R,2R,3S,5S)-2-FLUORO-9-AZABICYCLO[3.3.1]NONAN-3-YL)(METHYL)AMINO)PYRIDAZIN-3-YL)-2-METHYLBENZO[D]OXAZOL-5-OL AS A SPLICING MODULATOR FOR THE TREATMENT OF NEUROLOGICAL DISEASES



(B)

(57) Abstract: Described herein is 6-(6-(((1R,2R,3S,5S)-2-fluoro-9-aza bicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzo[d]oxazol-5-ol (structure B) as a small molecule splicing modulator (SMSM) of mRNA, such as pre-mRNA, encoded by genes, for the treatment of neurological and neurodegenerative diseases, such as e.g. Huntington's disease, and brain cancer.

WO 2025/006878 A1